Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.033404 USD
23.21 M USD
89.30 M USD
485.20 M
About Alphamab Oncology
Sector
Industry
CEO
Ting Xu
Website
Headquarters
Suzhou
Founded
2008
IPO date
Dec 12, 2019
Identifiers
3
ISIN KYG0330A1013
Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
HESC
HSBC ETFs PLC - HSBC MSCI Emerging Markets Small Cap Screened UCITS ETFWeight
0.05%
Market value
23.91 K
USD
XGEN
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF Accum-1C- USDWeight
0.05%
Market value
2.99 K
USD
Explore more ETFs
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange ALPHAMAB ONCOLOGY stocks are traded under the ticker ALMOF.
We've gathered analysts' opinions on ALPHAMAB ONCOLOGY future price: according to them, ALMOF price has a max estimate of 1.68 USD and a min estimate of 1.68 USD. Watch ALMOF chart and read a more detailed ALPHAMAB ONCOLOGY stock forecast: see what analysts think of ALPHAMAB ONCOLOGY and suggest that you do with its stocks.
Yes, you can track ALPHAMAB ONCOLOGY financials in yearly and quarterly reports right on TradingView.
ALPHAMAB ONCOLOGY is going to release the next earnings report on Mar 31, 2026. Keep track of upcoming events with our Earnings Calendar.
ALMOF net income for the last half-year is 2.95 M USD, while the previous report showed 29.49 M USD of net income which accounts for −89.99% change. Track more ALPHAMAB ONCOLOGY financial stats to get the full picture.
No, ALMOF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 15, 2026, the company has 420 employees. See our rating of the largest employees — is ALPHAMAB ONCOLOGY on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALPHAMAB ONCOLOGY EBITDA is 35.80 M USD, and current EBITDA margin is 27.81%. See more stats in ALPHAMAB ONCOLOGY financial statements.
Like other stocks, ALMOF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALPHAMAB ONCOLOGY stock right from TradingView charts — choose your broker and connect to your account.